Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16701561 | 0.87 | LMNA (0.52) | HRH3SMN1; SMN2LMNATLR9TLR8 | |
| SCHEMBL16701931 | 0.85 | SIRT6 (0.53) | HRH3SMN1; SMN2LMNATLR9TLR8 | |
| SCHEMBL23969975 | 0.81 | MAPT (0.44) | HRH3SMN1; SMN2LMNATLR9TLR8 | |
| SCHEMBL956959 | 0.81 | MAOA (0.48) | HRH3NOS3NOS1NOS2SMN1; SMN2 | |
| SCHEMBL16701629 | 0.79 | TGFBR1 (0.45) | HRH3SMN1; SMN2LMNACHEK2TGFBR1 | |
| SCHEMBL25725414 | 0.79 | LMNA (0.58) | HRH3SMN1; SMN2LMNAMAOAMAOB | |
| SCHEMBL16701811 | 0.79 | UTS2R (0.45) | SMN1; SMN2TSHRMAPTFPR2PROKR1 | |
| SCHEMBL22348656 | 0.78 | MAPT (0.54) | HRH3NOS3NOS1NOS2SMN1; SMN2 | |
| SCHEMBL30880140 | 0.78 | MAPT (0.54) | HRH3NOS3NOS1NOS2SMN1; SMN2 | |
| SCHEMBL16514882 | 0.78 | MAOA (0.45) | HRH3NOS3NOS1NOS2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | UNIVERSITY OF KANSAS (US) | 2020-06-23 | — | — | US | disclosed |
| US-20160272584-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | UNIVERSITY OF KANSAS (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272584-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | UNIVERSITY OF KANSAS (US) | 2016-09-22 | — | — | US | disclosed |
| EP-3066072-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | The University of Kansas (US) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015070091-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | THE UNIVERSITY OF KANSAS (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015070091-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | THE UNIVERSITY OF KANSAS (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | HSP90AB1, HSP90AA1, HSP90AB2P | HRH3 1161/4885NOS3 4171/4885NOS1 3569/4885 |
| US-20160272584-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | HRH3 1161/4885NOS3 4171/4885NOS1 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.